Medicine has long built its tools around the most common story, and those who live a different version of that story often find the door already closed. A study from Mayo Clinic reveals that between 70 and 85 percent of patients with atypical Alzheimer's disease — forms that first erode vision, language, or executive function rather than memory — are being turned away from promising anti-amyloid therapies, not because they are too ill to benefit, but because the tests used to measure their illness were never designed with them in mind. Published in Neurology in August 2026, the findings ask a
Study finds 70-85% of atypical Alzheimer's patients ineligible for new treatments
Patients with atypical Alzheimer's disease are being denied access to potentially disease-slowing treatments despite meeting early-stage disease criteria, limiting therapeutic options.